The Visikol team is proud to announce that it has secured two SBIR grants from the NIH and NSF for [...]
BASEL, Switzerland and WHITEHOUSE STATION, N.J. /PRWEB/ -- July 5, 2018 Enzyvant, a biopharmaceutical company focused on developing innovative treatments [...]
Visikol CEO and Co-Founder Dr. Michael Johnson was named to the Forbes 30 Under 30 list in 2017 and was [...]
October 26 and 17, 2018 | Sheraton Hotel | Boston, MA 3D cell culture is exploding. To capture the energy [...]
WHITEHOUSE STATION, N.J. (PRWEB) OCTOBER 15, 2018 Since the inception of the microscope, researchers and clinicians have characterized tissues through [...]
If you missed Thermo Fisher Scientific's webinar on LabRoots that focused on Visikol and Visikol's 3D cell culture assays you [...]
(PRWEB) AUGUST 01, 2018 Visikol CEO Dr. Michael Johnson has announced that through the rapid adoption of its 3Screen™ drug [...]
On October 25th at 12:00 PM EST Dr. Michael Johnson from Visikol will be presenting a webinar sponsored by Science [...]
On October 10th, Visikol will be presenting at TechFest in Boston at the Venture Cafe on 1 Broadway, Cambridge, MA. [...]
A common question for pharmaceutical companies developing therapeutics for neuroscience applications is the passage of small and large molecules across [...]